The pennsylvania project: Pharmacist intervention improved medication adherence and reduced health care costs

Health Affairs

Volumn 33, Issue 8, 2014, Pages 1444-1452

  Pringle, Janice L ^a   Boyer, Annette ^b   Conklin, Mark H ^c   McCullough, Jesse W ^d   Aldridge, Arnie ^e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CECity Com   (United States)

^c Pharmacy Quality Solutions   (United States)

^d Rite Aid   (United States)

^e RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RENIN; RENIN ANGIOTENSIN SYSTEM ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PHARMACIST; PHARMACY; PROGRAM COST EFFECTIVENESS; UNITED STATES; EDUCATION; FEE; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PENNSYLVANIA; PROFESSIONAL STANDARD; RISK FACTOR;

CHRONIC DISEASE; COMMUNITY PHARMACY SERVICES; EDUCATION, PHARMACY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PENNSYLVANIA; PHARMACISTS; PRESCRIPTION FEES; PROFESSIONAL ROLE; RISK FACTORS;

EID: 84905974089     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2013.1398     Document Type: Article

References (43)

1. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17): 1553-5.
2. Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care. 2005; 43(6):517-20.
3. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35.
4. Centers for Medicare and Medicaid Services. Medicare health and drug plan quality and performance ratings, 2013 Part C and Part D star rating technical notes. Baltimore (MD): CMS; 2013 May 22.
5. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574-80.
6. Traynor K. Poor medication adherence remains a problem. Am J Health Syst Pharm. 2012;69(21): 1850.
7. Smith M, Giuliano MR, Starkowski MP. In Connecticut: improving patient medication management in primary care. Health Aff (Millwood). 2011;30(4):646-54.
8. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008(2):CD000011.
9. Agres T. FIP panel: Pharmacists are an "untapped resource." Pharmacy Practice News [serial on the Internet]. 2013 May [cited 2014 Jun 5]. (Registration required). Available from: http://www.pharmacypractice news.com/ViewArticle.aspx?d= Policy&d_id=51&i=May+2013 &i_id=957&a_id=23214
10. Christensen DB, Farris KB. Pharmaceutical care in community pharmacies: practice and research in the US. Ann Pharmacother. 2006; 40(7-8):1400-6.
11. National Community Pharmacists Association. Medication adherence in America: a national report. Alexandria (VA): NCPA; 2013.
12. Agency for Healthcare Research and Quality. Draft systematic review: medication therapy management (unpublished report). Rockville (MD): AHRQ; 2013.
13. Totten AM, Wagner J, Tiwari A, O'Haire C, Griffin J, Walker M. Closing the quality gap: revisiting the state of the science. Vol. 5, Public reporting as a quality improvement strategy. Rockville (MD): AHRQ; 2012.
14. Christianson JB, Leatherman S, Sutherland K. Lessons from evaluations of purchaser pay-for-performance programs: a review of the evidence. Med Care Res Rev. 2008;65(6 Suppl):5S-35S.
15. Svarstad BL, Kotchen JM, Shireman TI, Crawford SY, Palmer PA, Vivian EM, et al. The Team Education and Adherence Monitoring (TEAM) trial: pharmacy interventions to improve hypertension control in blacks. Circ Cardiovasc Qual Outcomes. 2009;2(3):264-71.
16. Babor TF, Higgins-Biddle JC. Alcohol screening and brief intervention: dissemination strategies for medical practice and public health. Addiction. 2000;95(5):677-86.
17. Homer J, Hirsch G, Milstein B. Chronic illness in a complex health economy: the perils and promises of downstream and upstream reforms. Syst Dyn Rev. 2007;23(2-3):313-43.
18. McHorney CA. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin. 2009;25(1):215-38.
19. Miller SD, Duncan BL, Brown J, Sparks JA, Claud DA. The Outcome Rating Scale: a preliminary study of the reliability, validity, and feasibility of a brief visual analog measure. J Brief Ther. 2003;2(2):91-100.
20. Pringle J, Melczak M, Aldridge A, Snyder M, Smith R. Medication adherence and its relationship to the therapeutic alliance: results from an innovative pilot study within a community pharmacy MTM practice. INNOVATIONS in Pharmacy. 2011;2(1):1-16.
21. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8): 1280-8.
22. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-61.
23. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence [Internet]. Springfield (VA): Pharmacy Quality Alliance; 2012 [cited 2014 Jun 5]. Available from: http:// ep.yimg.com/ty/cdn/epill/ pdcmpr.pdf
24. Department of Health and Human Services. Medicare program; prospective payment system for hospital outpatient services; interim final rule. Fed Regist. 2000 Nov 13; 65(219)67798-846.
25. To access the Appendix, click on the Appendix link in the box to the right of the article online.
26. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics. 2005;61(4):962-73.
27. Sribney W. Comparison of standard errors for robust, cluster, and standardized estimators [Internet]. College Station (TX): Stata Corp.; 1998 Jul [cited 2014 Jun 5]. Available from: http://www.stata.com/ support/faqs/stat/cluster.html
28. Ferver K, Burton B, Jesilow P. The use of claims data in healthcare research. Open Public Health J. 2009;2:11-24.
29. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):357.e7-357.e27.
30. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
31. Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res. 2002;26(1):36-43.
32. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15(3): 199-236.
33. Bodenheimer T, Chen E, Bennett HD. Confronting the growing burden of chronic disease: can the US health care workforce do the job? Health Aff (Millwood). 2009;28(1): 64-74.
34. Kotecha D, Manzano L, Altman DG, Krum H, Erdem G, Williams N, et al. Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. Syst Rev. 2013; 2:7.
35. Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the European Depression in Diabetes (EDID) research consortium. Curr Diabetes Rev. 2009;5(2):112-9.
36. Katon W, Lin EH, Von Korff M, Ciechanowski P, Ludman E, Young B, et al. Integrating depression and chronic disease care among patients with diabetes and/or coronary heart disease: the design of the TEAMcare study. Contemp Clin Trials. 2010; 31(4):312-22.
37. Dragomir A, Côté R, White M, Lalonde L, Blais L, Bérard A, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010;13(1): 87-94.
38. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107(11):1662-66.
39. Baicker K, Taubman SL, Allen HL, Bernstein M, Gruber JH, Newhouse JP, et al. The Oregon experiment- effects of Medicaid on clinical outcomes. New Engl J Med. 2013; 368(18):1713-22.
40. Kuo AM. Opportunities and challenges of cloud computing to improve health care services. J Med Internet Res. 2011;13(3):e67.
41. Centers for Medicare and Medicaid Services. Choose higher quality for better health care [Internet]. Baltimore (MD): CMS; 2013 Jul [cited 2014 Jun 5]. Available from: http:// www.medicare.gov/Pubs/pdf/ 11226.pdf
42. Nau DP. Intersection of quality metrics and Medicare policy. Ann Pharmacother. 2011;45(12):1582-4.
43. Centers for Medicare and Medicaid Services. Guide to quality measurement for accountable care organizations starting in 2012: agreement period, performance year, and reporting period [Internet]. Baltimore (MD): CMS; 2011 [cited 2014 Jun 5]. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavings program/Downloads/ACO-Guide-Quality-Measurement-2012.pdf